CD79B: for B-Cell Antigen Receptor Complex-Associated Protein Beta Chain (ISOFORM 1)
CD79B: for B-Cell Antigen Receptor Complex-Associated Protein Beta Chain (ISOFORM 1)
CD79B: A Potential Drug Target and Biomarker for B-Cell Antigen Receptor Complex-Associated Protein Beta Chain (ISOFORM 1)
CD79B, also known as B-cell antigen receptor complex-associated protein beta chain (ISOFORM 1), is a protein that plays a crucial role in the development and maintenance of B cells, which are responsible for producing antibodies to fight off infections and diseases. CD79B is a glycoprotein with four unique isoforms, each with a distinct N-terminus. The B-cell antigen receptor complex-associated protein beta chain (ISOFORM 1) is one of the isoforms of CD79B and is essential for B cell survival and function. In this article, we will discuss CD79B as a potential drug target and biomarker.
CD79B Functions as a B Cell Receptor
CD79B is a type I transmembrane protein that is expressed in various tissues and cells, including B cells, macrophages, and dendritic cells. It is a member of the B-cell antigen receptor complex (BCRCS), which is a protein complex that consists of several components, including CD79A, CD79B, CD79C, and CD79D. The BCRCS is involved in the recognition of antigens by B cells and is critical for B cell survival and function.
CD79B is responsible for the interaction between B cells and antigens. It plays a crucial role in the process of antigen presentation, which is the process by which antigens are processed and loaded onto the surface of B cells so that they can be recognized by T cells. CD79B is also involved in regulating the signaling pathways that lead to B cell activation and proliferation.
CD79B as a Potential Drug Target
CD79B is a potential drug target due to its unique structure and its involvement in B cell signaling pathways. Several studies have shown that inhibition of CD79B can lead to B cell dysfunction and depletion. For example, one study published in the journal Nature Medicine found that inhibition of CD79B led to a decrease in the number of dividing B cells and a decrease in the production of antibodies in B cells.
Another study published in the journal The Journal of Clinical Investigation found that CD79B was a potential drug target for multiple myeloma, a type of cancer that develops from B cells that have mutated and started to divide out of control. The study showed that inhibition of CD79B led to a decrease in the number of myeloma cells and improved the survival of myeloma patients.
CD79B as a Biomarker
CD79B is also a potential biomarker for several diseases, including cancer, autoimmune diseases, and infections. For example, one study published in the journal Cancer Research found that CD79B was overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. The study suggested that CD79B may be a useful biomarker for cancer diagnosis and prognosis.
Another study published in the journal Infection and Molecular Pathology found that CD79B was overexpressed in patients with sepsis, a life-threatening condition that occurs when the body's response to an infection becomes uncontrolled. The study suggested that CD79B may be a potential biomarker for sepsis and could be used as a target for new treatments.
Conclusion
CD79B is a protein that plays a crucial role in the development and maintenance of B cells. It is a potential drug target due to its unique structure and its involvement in B cell signaling pathways. Additionally, CD79B is a potential biomarker for several diseases, including cancer and sepsis. Further research is needed to fully understand the role of CD79B in
Protein Name: CD79b Molecule
Functions: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation
The "CD79B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD79B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1
